RET and lung cancer: In line with previous reports, our analysis recapitulated the key targetable oncogenic fusion events in lung cancers, with a 4.2% frequency of ALK fusions, 1.3% of RET fusions, and 1.2% of ROS1 fusions (Fig. 1a and Supplementary Table 1).